InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1728328
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financials
TL;DR
InMed Pharma filed an 8-K on Nov 20th for Nov 19th event - check for Reg FD & financials.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on November 20, 2024, reporting an event on November 19, 2024. The filing pertains to Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.
Why It Matters
This 8-K filing indicates that InMed Pharmaceuticals Inc. has made a regulatory disclosure and filed financial statements, which could contain important updates for investors.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events but doesn't inherently signal high risk without further context from the filing's content.
Key Numbers
- 001-39685 — Commission File Number (Identifies the company's filing with the SEC)
- 98-1428279 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- November 19, 2024 (date) — Earliest event reported
- November 20, 2024 (date) — Date of report
- British Columbia (jurisdiction) — State of incorporation
- Vancouver, Canada (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing on November 19, 2024?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items of disclosure, but the specific event is not detailed in the provided header information.
What is the exact nature of the 'Regulation FD Disclosure' mentioned?
The provided text does not specify the details of the Regulation FD Disclosure, only that it is part of the filing.
Are there any new financial statements or exhibits included with this filing?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information, indicating their inclusion.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada, V6C 3E8.
What is the company's fiscal year end?
The company's fiscal year ends on June 30 (0630).
Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-20 15:45:23
Filing Documents
- ea0222020-8k_inmed.htm (8-K) — 27KB
- ea022202001ex99-1_inmed.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-100527.txt ( ) — 240KB
- inm-20241119.xsd (EX-101.SCH) — 3KB
- inm-20241119_lab.xml (EX-101.LAB) — 33KB
- inm-20241119_pre.xml (EX-101.PRE) — 22KB
- ea0222020-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 19, 2024, the Company announced that a peer-reviewed scientific study entitled "Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal Biofactors. This Company-sponsored study demonstrates the biological activity of cannabinol ("CBN") and its potential anti-inflammatory effects in skin diseases. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated November 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: November 20, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2